Reportstack

VCAM-1 (Vascular Cell Adhesion Molecule-1) Gene Expression Inhibitor -Pipeline Insights, 2014

 

Naperville, IL -- (SBWIRE) -- 07/23/2014 -- Reportstack, provider of premium market research reports announces the addition of VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor -Pipeline Insights, 2014 market report to its offering DelveInsights,VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor. This report provides information on the therapeutic development based on the VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.

Scope
The report provides a snapshot of the global therapeutic landscape of VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor

The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

The report reviews key players involved in the therapeutics development for VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor and also provide company profiling

The report also gives the information of dormant and discontinued pipeline projects

Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

Complete MOA intelligence and complete understanding over therapeutics development for VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor

Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.

Devise corrective measures for pipeline projects by understanding VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor pipeline depth and focus of Indication therapeutics

Developing strategic initiatives to support your drug development activities.

Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/163504/vcam-1-vascular-cell-adhesion-molecule-1-gene-expression-inhibitor-pipeline-insights-2014.html

Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604